Vaniam Group Appoints Robert L. Coleman as Company's Inaugural Chief Medical Officer
CHICAGO, May 22, 2023 /PRNewswire/ -- Vaniam Group today announced the appointment of Robert L. Coleman, MD, FACOG, FACS, as the company's inaugural Chief Medical Officer. One of the country's preeminent gynecologic oncologists over the past three decades, Dr. Coleman will drive medical excellence across the organization, expand the company's engagement with other healthcare providers and key opinion leaders, provide clinical guidance to client deliverables, and mentor teams and individuals throughout Vaniam Group. Serving as a key part of the Executive Committee, Dr. Coleman will report directly to Vaniam Group's CEO and founder, Deanna B. van Gestel.
- CHICAGO, May 22, 2023 /PRNewswire/ -- Vaniam Group today announced the appointment of Robert L. Coleman, MD, FACOG, FACS, as the company's inaugural Chief Medical Officer.
- Serving as a key part of the Executive Committee, Dr. Coleman will report directly to Vaniam Group's CEO and founder, Deanna B. van Gestel.
- As our Chief Medical Officer, Dr. Coleman will be an invaluable resource to our biopharma clients, and we are honored to have him join our team."
- Immediately prior to joining Vaniam Group, Dr. Coleman was the the Chief Scientific Officer for US Oncology Research (USRI) and the Chief Medical Officer for Sarah Cannon Research Institute (SCRI), a joint venture research organization between USOR and SCRI.